Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 2, 2001, Pages 181-185

  Moschetta, A ^a,b   Stolk, M F J ^c   Rehfeld, J F ^d   Portincasa, P ^b   Slee, P H T H J ^c   Koppeschaar, H P F ^a   Van Erpecum, K J ^a   Vanberge Henegouwen, G P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b POLICLINICO   (Italy)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; OCTREOTIDE;

ACROMEGALY; ADULT; AGED; ARTICLE; CHOLECYSTOKININ BLOOD LEVEL; CLINICAL ARTICLE; DIET RESTRICTION; ECHOGRAPHY; FEMALE; GALLBLADDER MOTILITY; GALLSTONE; HUMAN; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH EMPTYING;

ACROMEGALY; AGED; AGED, 80 AND OVER; CHEMISTRY, PHARMACEUTICAL; CHOLECYSTOKININ; CHOLELITHIASIS; FEMALE; GALLBLADDER EMPTYING; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 0035122649     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00924.x     Document Type: Article

References (23)

1. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly
2. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995
3. Engl J Med
4. Gallstone during octreotide therapy
5. Effects of long term octreotide on gall stone formation and gall bladder function
6. Octreotide-associated biliary tract dysfunction and gallstone formation: Pathophysiology and management
7. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly
8. The gallstone story
9. Four years' treatment of resistant acromegaly with octreotide
10. Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment
11. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men
12. Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly
13. Effects of atropine, proglumide, and somatostatin analogue (SMS 201-995) on bombesin-induced gallbladder contraction and CCK secretion in humans
14. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly
15. Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly
16. Disorders of bile acid metabolism in cholesterol gallstone disease
17. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones
18. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly
19. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients
20. Sandostatin LAR: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients
21. A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction
22. Measurement of gastric emptying time by real-time ultrasonography
23. Accurate measurement of cholecystokinin in plasma